Klivira
Request demo

Streamlining Medicare Mavyret Prior Authorization Workflows

Navigating the complexities of **Medicare Mavyret prior authorization** requires precise understanding of both Original Medicare and Medicare Advantage plan requirements. Klivira provides the automation infrastructure to streamline this critical process.

For high-volume medications like Mavyret, an oral antiviral for chronic Hepatitis C, efficient prior authorization is crucial for patient access and revenue cycle integrity. Healthcare organizations must contend with varied payer requirements, particularly across the diverse landscape of Medicare plans, from Original Medicare to numerous Medicare Advantage and Part D offerings.

Mavyret and the Medicare Coverage Landscape

Mavyret (glecaprevir/pibrentasvir) is indicated for chronic Hepatitis C virus (HCV) infection across genotypes. While Original Medicare's prior authorization scope is limited, coverage for HCV treatments like Mavyret typically falls under Medicare Part D for pharmacy benefits or, in specific scenarios, Part B for administered drugs, subject to medical necessity criteria, National Coverage Determinations (NCDs), and Local Coverage Determinations (LCDs).

Navigating Medicare Part D Prior Authorization for Mavyret

The majority of **Medicare Mavyret prior authorization** requests are processed through Medicare Part D plans. These plans, administered by private insurers, establish their own formularies, step-therapy protocols, and quantity limits, all subject to CMS approval. Klivira integrates directly with Part D Pharmacy Benefit Managers (PBMs) and plan portals to submit electronic prior authorization (ePA) requests efficiently, leveraging standards like NCPDP SCRIPT.

Original Medicare (Part A & B) Prior Authorization Considerations

For Original Medicare, prior authorization for drugs like Mavyret is less common, primarily applying if the drug is administered in an outpatient setting and falls under specific programs. Where PA is required for Part B-covered services, submissions are routed through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction. Examples of MACs include Noridian, NGS, WPS, Palmetto, FCSO, and Novitas.

Key Submission Channels for Medicare Mavyret PA

  • Medicare Part D PBMs and plan-specific portals for pharmacy benefits.
  • MAC-specific portals or X12 278 transactions for Original Medicare Part B services requiring PA.
  • ePA platforms leveraging NCPDP SCRIPT for Part D submissions.
  • Direct EMR integration points for streamlined data flow to Klivira.

Policy Adherence and Denial Prevention

Adherence to CMS National Coverage Determinations (NCDs) and MAC-issued Local Coverage Determinations (LCDs) is paramount for successful **Medicare Mavyret prior authorization**. Klivira's platform incorporates NCD/LCD-aware logic, helping to ensure submissions meet specific medical necessity criteria and documentation requirements. This proactive approach reduces common denial reasons related to insufficient clinical information or non-adherence to coverage policies.

Klivira's Approach to Medicare Mavyret PA Automation

Klivira's platform streamlines the prior authorization process for Mavyret across the Medicare ecosystem. We automate data extraction from EMRs, intelligently route requests to the correct MAC or Part D PBM, and provide real-time status updates. This reduces administrative burden, accelerates patient access to critical HCV treatment, and improves revenue cycle efficiency for your organization.

Frequently asked questions

Does Original Medicare require prior authorization for Mavyret?

Original Medicare (Parts A and B) has a limited scope for prior authorization. Mavyret, as an oral medication, typically falls under Medicare Part D for pharmacy benefits, where PA is common. If Mavyret were administered in an outpatient setting and subject to specific Part B PA programs, then a MAC-specific PA would apply.

How do Medicare Part D plans determine Mavyret coverage?

Medicare Part D plans, operated by private insurers, establish their own formularies and utilization management criteria for drugs like Mavyret. These criteria, including step therapy and quantity limits, must be approved by CMS. Providers should consult the specific Part D plan's formulary for details on coverage and PA requirements.

Which entities handle Mavyret prior authorizations for Medicare?

For Medicare Part D, prior authorizations are handled by the specific Part D plan's Pharmacy Benefit Manager (PBM) or directly by the plan. For the rare instances where Original Medicare Part B requires PA for Mavyret-related services, the relevant Medicare Administrative Contractor (MAC) for your jurisdiction processes the request.

What are common reasons for Mavyret PA denials under Medicare?

Common denial reasons for Mavyret PA under Medicare Part D often include failure to meet step-therapy requirements, insufficient documentation of medical necessity or prior treatment failures, or non-adherence to quantity limits. For Original Medicare, denials could relate to non-compliance with NCDs or LCDs.

How does Klivira integrate with Medicare PA processes for Mavyret?

Klivira integrates with EMRs to extract necessary clinical data, then intelligently routes Mavyret prior authorization requests. For Part D, we connect with PBMs and plan portals. For Original Medicare, where applicable, we route through MAC-jurisdiction specific channels, leveraging NCD/LCD-aware logic to streamline submissions.

Related coverage

Other mavyret prior authorization by payer

Other mavyret prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo